Author(s): Wang, HC (Wang, Hwei-Chung); Chiu, CF (Chiu, Chang-Fang); Tsai, RY (Tsai, Ru-Yin); Kuo, YS (Kuo, Yung-Shun); Chen, HS (Chen, Hua-Shiang); Wang, RF (Wang, Rou- Fen); Tsai, CW (Tsai, Chia-Wen); Chang, CH (Chang, Chao-Hsiang); Lin, CC (Lin, Cheng- Chieh); Bau, DT (Bau, Da-Tian)
Title: Association of Genetic Polymorphisms of EXO1 Gene with Risk of Breast Cancer in Taiwan
Source: ANTICANCER RESEARCH, 29 (10): 3897-3901 OCT 2009 Language: English
Document Type: Article
Author Keywords: EXO1; polymorphism; breast cancer; carcinogenesis
KeyWords Plus: SINGLE NUCLEOTIDE POLYMORPHISM; DNA MISMATCH REPAIR;
NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1;
HUMAN EXONUCLEASE-I; ORAL-CANCER; XRCC4 GENE; SUSCEPTIBILITY;
IDENTIFICATION; POPULATION
Abstract: The aim of the present study was to evaluate the association between the
polymorphisms of the EXO1 gene and the risk of breast cancer in central Taiwan. Patients and Methods: In this hospital-based study, the association of EXO1 A1419G (rs3754093), C908G (rs10802996), A238G (rs1776177), C498T (rs1635517), K589E (rs1047840), G670E
(rs1776148), C723R (rs1635498), L757P (rs9350) and C3114T (rs851797) polymorphisms with breast cancer risk in a central Taiwanese population was investigated. In total, 1,272 patients with breast cancer and 1,272 age- and gender-matched healthy controls recruited from the China Medical University Hospital were genotyped. Results: A significantly different distribution was found in the frequency of the EXO1 K589E genotype, but not the other genotypes, between the breast cancer and control groups. The A allele EXO1 K589E conferred a significantly (p=0.000025) increased risk of breast cancer. As for the rest of the polymorphisms, there was no difference in distribution between the breast cancer and control groups. Conclusion: Our results provide evidence that the A allele of EXO1 K589E may be associated with the development of breast cancer and may be a useful biomarker for breast cancer detection and primary prevention.
Addresses: [Wang, Hwei-Chung; Chiu, Chang-Fang; Tsai, Ru-Yin; Kuo, Yung-Shun; Chen, Hua-Shiang; Wang, Rou-Fen; Tsai, Chia-Wen; Chang, Chao-Hsiang; Lin, Cheng-Chieh; Bau, Da-Tian] China Med Univ Hosp, Terry Fox Canc Res Lab, Taichung 404, Taiwan; [Wang, Hwei-Chung] China Med Univ Hosp, Dept Surg, Taichung 404, Taiwan; [Chiu, Chang-Fang]
China Med Univ Hosp, Dept Hematol Oncol, Taichung 404, Taiwan; [Lin, Cheng-Chieh] China Med Univ Hosp, Dept Family Hlth, Taichung 404, Taiwan; [Tsai, Chia-Wen; Bau, Da-Tian]
China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan; [Bau, Da-Tian] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Lin, Cheng-Chieh] Asia Univ, Coll Hlth Sci,
Taichung, Taiwan
Reprint Address: Bau, DT, China Med Univ Hosp, Terry Fox Canc Res Lab, 2 Yuh Der Rd, Taichung 404, Taiwan.
E-mail Address: datian@mail.cmuh.org.tw Funding Acknowledgement:
Funding Agency Grant Number
China Medical University Hospital DMR-98-045 Terry Fox Cancer Research Foundation
National Science Council NSC 98-2320-B-039-010-MY3
We appreciate Hsiu-Min Hsieh and the Tissue-Bank at China Medical University Hospital for their technical assistance. This study was supported by research grants from the China Medical University Hospital (DMR-98-045), Terry Fox Cancer Research Foundation and the National Science Council (NSC 98-2320-B-039-010-MY3, first year).
Cited References: BAU DT, 2004, CANCER RES, V64, P5013.
BAU DT, 2006, CANCER LETT, V240, P1, DOI 10.1016/j.canlet.2005.08.003.
BAU DT, 2007, ANTICANCER RES, V27, P2893.
BAU DT, 2007, CARCINOGENESIS, V28, P1726, DOI 10.1093/carcin/bgm109.
BAU DT, 2008, ORAL ONCOL, V44, P1047, DOI 10.1016/j.oraloncology.2008.02.008.
CHIU CF, 2008, ANN SURG ONCOL, V15, P514, DOI 10.1245/s10434-007-9674-3.
CHIU CF, 2008, ANTICANCER RES, V28, P267.
CHIU CF, 2008, ORAL ONCOL, V44, P582, DOI 10.1016/j.oraloncology.2007.07.006.
CHIU CF, 2008, ORAL ONCOL, V44, P898, DOI 10.1016/j.oraloncology.2007.11.007.
DUMITRESCU RG, 2005, J CELL MOL MED, V9, P208.
HANAHAN D, 2000, CELL, V100, P57.
IYER RR, 2006, CHEM REV, V106, P302.
JAGER AC, 2001, ONCOGENE, V20, P3590.
JAGMOHANCHANGUR S, 2003, CANCER RES, V63, P154.
JIN GF, 2008, LUNG CANCER, V60, P340, DOI 10.1016/j.lungcan.2007.11.003.
KAMANGAR F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308.
LI GM, 2003, FRONT BIOSCI, V8, P997.
LIBERTI SE, 2004, MOL CANCER RES, V2, P427.
MARTI TM, 2002, J CELL PHYSIOL, V191, P28.
MODRICH P, 1996, ANNU REV BIOCHEM, V65, P101.
RASMUSSEN LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41.
SCHMUTTE C, 1998, CANCER RES, V58, P4537.
SCHMUTTE C, 2001, J BIOL CHEM, V276, P33011.
SINGLETARY SE, 2003, ANN SURG, V237, P474.
THOMPSON E, 2004, CLIN GENET, V65, P215.
TISHKOFF DX, 1997, P NATL ACAD SCI USA, V94, P7487.
TISHKOFF DX, 1998, CANCER RES, V58, P5027.
TRAN PT, 2001, P NATL ACAD SCI USA, V98, P9760.
WANG YC, 2003, J CLIN INVEST, V111, P887, DOI 10.1172/JCI200315475.
WEI KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603.
WILSON DM, 1998, NUCLEIC ACIDS RES, V26, P3762.
WU Y, 2001, GASTROENTEROLOGY, V120, P1580.
XINARIANOS G, 2000, CANCER RES, V60, P4216.
YAMAMOTO H, 2005, CARCINOGENESIS, V26, P411, DOI 10.1093/carcin/bgh335.
Cited Reference Count: 34 Times Cited: 0
Publisher: INT INST ANTICANCER RESEARCH
Publisher Address: EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE
ISSN: 0250-7005
29-char Source Abbrev.: ANTICANCER RES ISO Source Abbrev.: Anticancer Res.
Source Item Page Count: 5 Subject Category: Oncology ISI Document Delivery No.: 515QL
